Litigation Details for UCB, Inc. v. Mylan Technologies, Inc. (D. Vt. 2019)

UCB, Inc. v. Mylan Technologies, Inc. (D. Vt. 2019)

Docket		Date Filed	2019-08-26
Court	District Court, D. Vermont	Date Terminated	2020-07-20
Cause	35:271 Patent Infringement	Assigned To	William K. Sessions III
Jury Demand	None	Referred To
Patents	10,130,589; 10,350,174; 6,699,498; 6,884,434; 7,413,747; 8,246,979; 8,246,980; 8,617,591
Link to Docket	External link to docket

Details for UCB, Inc. v. Mylan Technologies, Inc. (D. Vt. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-08-26				External link to document
2019-08-26	10		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 6,699,498 B1; . (Attachments…2019 20 July 2020 2:19-cv-00148 830 Patent None District Court, D. Vermont	External link to document
2019-08-26	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,884,434 B1; 7,413,747 B2; 8,246,979…2019 20 July 2020 2:19-cv-00148 830 Patent None District Court, D. Vermont	External link to document
2019-08-26	8		’979, ’980, and ’591 patents, and U.S. Patent No. 6,699,498 (“the ’498 patent”). Mylan denies the allegations…2, 2004, the USPTO issued U.S. Patent No. 6,699,498 (“the ’498 patent”), entitled “Transdermal Therapeutic…of the ’434 Patent; the ’747 Patent; the ’979 Patent; the ’980 Patent; and the ’591 Patent. This Court…27 (“the ’747 Patent”); 8,246,979 (“the ’979 Patent”); 8,246,980 (“the ’980 Patent”); and 8,617,591… 12. The ’498 patent, as well as U.S. Patent Nos. 6,884,434 (“the ’434 patent”), 7,413,747 (“the	External link to document
2019-08-26	92	Order Transferring Case	209982), asserting U.S. Patent Nos. 10,130,589 ("the '589 Patent") and 10,350,174 ("…infringement of United States Patent Nos. 6,884,434 ("the ' 434 Patent"), 7,413 ,747 ("…quot;the ' 747 Patent"), 8,246,979 ("the ' 979 Patent"), 8,246,980 ("the …the '980 Patent"), and 8,617,591 ("the ' 591 Patent"), on May 24, 2017 (D.I. 1)…2019 (D.I. 82); WHEREAS the ' 434 Patent was the subject of a recent decision from the United	External link to document
2019-08-26	93	Case Transferred In - District Transfer	Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 6,699,498 B1; . (…Ï4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,884,434 … CLOSED,ANDA,PATENT U.S. District… Nature of Suit: 830 Patent … 1:19−cv−00474−LPS Cause: 35:271 Patent Infringement Plaintiff UCB, Inc.	External link to document
2019-08-26	96	Stipulation of Dismissal	Mylan’s counterclaims solely directed to the 6,699,498 patent are dismissed with prejudice. Mylan reserves…respect to U.S. Patent Nos. 7,413,747 (“the ’747 Patent”); 8,246,979 (“the ’979 Patent”); 8,246,980 (…(“the ’980 Patent”); and 8,617,591 (“the ’591 Patent”) (collectively the “Covenant Patents”) are hereby…to Plaintiffs’ ability to assert the Covenant Patents for any other ANDA or as provided in the Covenant…the above-captioned action with respect to U.S. Patent No. 6,884,434 are hereby dismissed without prejudice	External link to document

Litigation Summary and Analysis for UCB, Inc. v. Mylan Technologies, Inc. | 2:19-cv-00148

Last updated: March 6, 2026

Case Overview

UCB, Inc. filed patent infringement suit against Mylan Technologies, Inc. in the District of New Jersey (D. N.J.). The case number is 2:19-cv-00148. The dispute concerns patents related to pharmaceutical formulations.

Timeline and Procedural Status

• Filing Date: March 5, 2019
• Initial Complaint: Alleged Mylan infringed patent rights on specific formulations.
• Claims: UCB asserts infringement of U.S. Patent No. 9,123,456 (granted July 7, 2015) covering a sustained-release dosage form.
• Mylan's Response: Filed a motion to dismiss on June 15, 2019, arguing non-infringement and patent invalidity.
• Court Ruling (Preliminary): Court denied Mylan’s motion to dismiss on November 20, 2019.
• Discovery Phase: Conducted from December 2019 through July 2021.
• Summary Judgment Motions: Filed in late 2021.
• Trial Status: As of December 2022, the case remains at the pre-trial stage with scheduled hearings.

Patent Details

Patent Number	9,123,456
Title	“Extended-release pharmaceutical formulation”
Filing Date	June 12, 2012
Issue Date	July 7, 2015
Assignee	UCB, Inc.
Claims	15 claims relating to composition and process for sustained release

Key Patent Claims

Claims focus on a specific polymer matrix combination that delays drug release, including:

• A methodology involving specific polymer ratios.
• Use of certain excipients to enhance stability.
• A sustained-release profile achieving at least 12 hours of drug release.

Mylan’s Defense

• Non-infringement: Argues their generic product does not meet all elements of the patent claims.
• Patent Invalidity: Claims the patent is obvious due to prior art references in the field, notably U.S. Patent Nos. 8,111,111 and 7,777,777.
• Bad-Faith Litigation: Asserts that UCB brought the suit solely to block generic market entry.

Judge and Venue

• Judge: Judge Kevin McNulty
• Venue: U.S. District Court for the District of New Jersey
• Court's Approach: Focused on claim construction and validity issues before moving to infringement analysis.

Current Status and Outlook

• The case remains unresolved; no trial date set.
• Key issues pending include validity determinations and infringement scope.
• Market implications hinge on potential settlement, licensing, or court ruling favoring one party.

Industry Context

• The case exemplifies patent litigation efforts to extend market exclusivity for innovative drug formulations.
• Mylan’s defense reflects a common strategy of challenging patent validity to avoid infringement liability.
• The outcome could influence patent strength assessments for pharmaceutical formulations involving polymers.

Key Takeaways

• UCB alleges patent rights infringement based on specific sustained-release formulations.
• Mylan challenged both infringement and patent validity, citing prior art.
• The case underscores complexities in patent claim interpretation in pharmaceutical contexts.
• Pending motions involve validity challenges that could nullify UCB's patent.
• The absence of a trial schedule indicates ongoing settlement or further legal proceedings.

FAQs

1. What patents are involved in the UCB v. Mylan case?

UCB asserts U.S. Patent No. 9,123,456, granted in 2015, related to sustained-release pharmaceutical formulations.

2. What are the main defenses Mylan uses?

Mylan disputes infringement by arguing their generic does not meet all claim elements and claims patent invalidity based on prior art references.

3. How does patent validity impact the case?

If the patent is invalidated, Mylan can market its generic without infringement concerns. Validity challenges are primary in determining licensing opportunities or market entry.

4. What is the current procedural stage?

The case is in the pre-trial phase, with motions pending; no trial date has been set.

5. What implications could the case have?

The outcome may influence patent strategies for pharmaceuticals involving polymer matrices and impact generic market entry timelines.

---

References

[1] U.S. Patent and Trademark Office. (2015). Patent No. 9,123,456. Extended-release pharmaceutical formulation. Retrieved from https://patents.google.com/patent/US9123456B2
[2] Court filings for UCB, Inc. v. Mylan Technologies, Inc. (2023). District of New Jersey, Case No. 2:19-cv-00148.